NCT01772212View on ClinicalTrials.gov

Bioequivalence Study for Terbinafine 250 mg

PHASE1CompletedINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

February 24, 2011

Primary Completion Date

March 15, 2011

Study Completion Date

March 15, 2011

Conditions

Mycoses

Interventions

DRUG

Terbinafine 250 mg

Test product

DRUG

Terbinafine 250 mg

Reference product

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT01772212 - Bioequivalence Study for Terbinafine 250 mg | Biotech Hunter | Biotech Hunter